RP12146
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1bActive
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Phase 1b
Status
Active
Company
About Rhizen Pharmaceuticals
Rhizen Pharmaceuticals is a private, clinical-stage biotech company developing novel small molecule therapeutics for oncology and inflammation. The company has a pipeline with assets in Phase 1 and Phase 2 clinical trials, including Tenalisib for metastatic triple-negative breast cancer (TNBC) and RP12146 for metastatic castration-resistant prostate cancer (mCRPC). Rhizen operates with a capital-efficient model, aiming to progress assets to clinical proof-of-concept before out-licensing to global partners for registration and commercialization. The company emphasizes full intellectual property ownership of its programs.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |
| SYNC-T | Syncromune | Phase 2 |